Commercial Impact

AdiCyte offers high quality cryopreservation of adipose tissue and stem cells for patients in cosmetics, augmentation, regenerative medicine, and tissue engineering. By banking adipose tissue following surgical procedures, patients can save a biological resource for emerging treatments and procedures.

Advanced Solutions Life Sciences (ASLS) is a subsidiary of 30-year old Advanced Solutions, Inc. (ASI), with over 150 employees and 14 offices in the United States, and is headquartered within a 15,000 square foot facility in Louisville, Kentucky. ASLS exists to support the medical research community through advanced technology and continual innovation.

Akhu Therapeutics, Inc is a life sciences company that is committed to discovering, developing, and commercializing novel medicines to transform the lives of people and companion animals with life-altering central nervous system (CNS) disorders. They use a focused, practical, and deliberate approach to drug development when pursuing expedited pathways in their efforts to deliver new treatments.

Angiomics is a biotechnology start-up specializing in the production of vascularized human tissue, including microvasculature tissue. The fully vascularized 3-D tissue provides an ideal platform for both drug discoveries and testing through phenotypic screening, enabling faster and more efficient discoveries of new compounds.

Anivive hopes to start a new era in pet medicine by changing the way therapeutics and vaccines are developed for companion animals. They work to provide new solutions for unmet and underserved medical needs, such as lymphoma cancer or valley fever, by intersecting technology and animal health.

Aqualung Therapeutics (Aqualung Therapeutics Corporation) consists of a coalition of academic leaders, entrepreneurs, and translational scientists with expertise in precision medicine, exploring NAMPT as a key target and novel diagnostic in acute and chronic lung inflammatory disorders.

Biousian Biosystems (BBI) is committed to improving the lives of patients living in chronic pain or struggling conditions which lead to chronic pain. Using its CarboSyn® technology platform, BBI builds drugs that have unique selectivity and potency for targets called G-protein coupled receptor or “GPCRs”. The company has specific strengths in related medicinal chemistries and pharmacology.

bioVidria, Inc. is a research-based company focused on newly invented materials for protein analysis to serve the pharmaceutical, biomedical, and biotechnology markets. The core technology of the company is high purity silica with specialized coatings to direct each application.

Cancer Prevention Pharmaceuticals, Inc. is developing novel therapeutic agents that make possible the treatment of risk factors for cancer. Their clinical focus is in familial adenomatous polyposis and the prevention of recurrence in colon cancer survivors, neuroblastoma, and other cancers.

EVPSenors is developing sensing technology for non-invasive measurement of intraocular pressure (IOP). Elevated IOP is associated with glaucoma, an eye disease that if left untreated can lead to blindness.

GAAS Corporation is a research and professional services company in the field of bioscience and natural products. GAAS Analytical offers expertise and experience to the dietary supplement and biotechnology industry, including research institutes and universities, small and medium biotechnology firms, raw material suppliers, finished product manufacturers, and legal professionals.

GenVault provides sample management solutions for disease diagnosis, research, identification, and criminal investigations. The company developed the GenTegra DNA technology for stabilizing DNA biosamples with antimicrobial activity for dry, room temperature transport and biobanking.

GUSA technology is based on the low-cost manufacture of DNA microarrays.

i-calQ has developed the world’s first smartphone-based point-of-care integrated mobile diagnosis and decision support system. Using a drop of blood or saliva, a test can be performed and the results interpreted anywhere and anytime. This technology does not require costly equipment or laboratory personnel. Accurate results, clinical interpretation, and recommendations for additional workup or treatment are delivered within minutes at a fraction of the cost of a comparable laboratory test and physician evaluation.

Luceome offers a rapid method of screening kinase inhibitor drugs for cancer treatment. Luceome enables drug discovery by leveraging their assay technology for identification of drugs against kenases.

Montigen was acquired by SuperGen and no longer exists in name. Montigen uses its drug screening method to discover and create promising anti-cancer compounds. Candidate drugs inhibit aurora-A kinase, a gene amplified in most human cancer cells, and small molecules that target tyrosine-kinase receptors that play critical roles in transducing growth signals to cancer cells.

Q Therapeutics has adopted a unique approach to developing human cell-based therapies for debilitating – and currently incurable – diseases of the brain, spinal cord and the central nervous system. Their revolutionary approach focuses on glial cells – non-neuronal cells in the CNS that are essential for supporting, repairing, and maintaining normal neuron function and health.

RediRipe LLC develops ethylene detecting stickers for use in evaluating the ripeness of climacteric fruits and vegetables. Examples include apples, peaches, pears, and some varieties of melons. The devices change from a pale yellow to a dark blue when the fruit has a high rate of ethylene release indicative of a late stage of maturation.

Reglagene is focused on cancer therapeutics, and the commercialization of the DNA Quadruplex discoveries from the labs of Dr. Laurence Hurley. Their invention is a small molecule that reduces hTERT, which is highly activated in cancer cells.

Regulonix was founded to address the growing opioid epidemic. Their science approaches the issue of treating pain in an entirely new way that is targeted and highly selective, resulting in non-addictive solutions.

Sonora Bioconsulting integrates business development, intellectual asset management, and technology transfer for the life science industry to protect, grow, and leverage early stage assets to build and establish startups or increase value in existing companies.

Sonora Transplants developed disease resistant rootstocks for greenhouse/controlled environment crop production. Goals include developing a way of growing vaccines inside of tomatoes as part of a foray into agro-pharmaceuticals.

Synactix Pharmaceuticals, Inc is a biotechnology company focused on developing therapies for the treatment of human disease using precision medicine. Projects are centered around “single-agent polypharmacology” where a single-agent is engineered to shut down multiple facets of human disease.

Teleport Pharmaceuticals is dedicated to novel peptide neurotransmitter based drug design for future therapeutics. They are the nexus of the groundbreaking research of three University of Arizona professors (Polt, Heien, and Streicher).

TetraGene is a platform technology company focused on developing therapeutics based on DNA channel technology. Their approach is utilizing a variety of therapeutic systems; including small molecules and structured nucleic acids (DNA and RNA).

Theregen, Inc. is a regenerative medicine company based in San Francisco, California, USA, that develops cell-based therapies for patients with cardiovascular and vascular disease. The company is conducting a Phase I human clinical safety trial at two US sites for its lead product, AngineraTM, a cell-based epicardial patch therapy. Anginera is designed to promote blood vessel growth in damaged cardiac tissue, stimulate wound healing and, potentially, to restore cardiac function in patients with heart failure.

Topical Technologies develops new topical agents for the prevention of skin cancer.

Valley Fever Solutions, Inc. (VFS) is moving Nikkomycin Z (NikZ) to the market as a therapy and potential cure for Valley Fever. VFS is studying pharmaceutical compounds and improved methods of diagnosing cocci and vaccine candidates intended for the prevention of valley fever.

Yumanity is dedicated to protecting the vitality of the mind. They are working to identify and develop new, disease-modifying therapies for Alzhiemer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).